Table S1-S7, Figure S1-S11, Supplementary Experimental Procedures from PSF Promotes ER-Positive Breast Cancer Progression via Posttranscriptional Regulation of ESR1 and SCFD2

Abstract

This file contains Supplementary Figure S1. High PSF expression is positively associated with poor prognosis of breast cancer patients.; Supplementary Figure S2. ESR1 expression is elevated in endocrine resistance model hydroxytamoxifen-resistant OHTR cells and ESR1 knockdown represses OHTR cell proliferation.; Supplementary Figure S3. PSF knockdown represses the proliferation and cell cycle progression of ER-positive T47D breast cancer cells.; Supplementary Figure S4. PSF correlates with estrogen signaling pathway and regulates the expression of estrogen target genes without altering its own mRNA expression.; Supplementary Figure S5. PSF regulates ESR1 expression at the posttranscriptional level.; Supplementary Figure S6. PSF overexpression enhances ESR1 expression and overcomes OHT-dependent cell proliferation inhibition.; Supplementary Figure S7. Mapping of PSF-immunoprecipitated RNAs in the vicinity of known PSF-associated genes or PSF-nonassociated gene and identification of PSF-binding RNAs with RIP-seq.; Supplementary Figure S8. PSF regulates SCFD2, TRA2B and ASPM expression at posttranscriptional level in ER-positive breast cancer cells.; Supplementary Figure S9. PSF knockdown promotes nuclear accumulation of SCFD2 and TRA2B but not ASPM in ER-positive breast cancer cells, whereas high expression of TRA2B and ASPM is significantly associated with shorter survivals of breast cancer patients.; Supplementary Figure S10. High expression of PSF-targeted SCFD2 is associated with shorter relapse-free survival of ER-positive breast cancer patients and SCFD2 knockdown represses T47D cell proliferation.; Supplementary Figure S11. PSF siRNA injection downregulates ER+ expression in xenograft tumors inoculated with tamoxifen-resistant cancer cells without altering mouse body weight and pre-mRNA expression of ESR1 and SCFD2.; Supplementary Table S1. Primers used in this study.; Supplementary Table S2. Association between PSF status and clinicopathological parameters in Shikoku Cancer Center cohort including 73 cases of human ER-positive breast cancers.; Supplementary Table S3. Clinicopathological parameters associated with distant disease-free or overall survival in univariate and multivariate analyses in Shikoku Cancer Center cohort (n = 73).; Supplementary Table S4. Association between PSF status and clinicopathological parameters in Toranomon Hospital cohort including 114 breast cancer cases.; Supplementary Table S5. Clinicopathological parameters associated with overall survival in univariate and multivariate analyses in Toranomon Hospital cohort (n = 114).; and Supplementary Experimental Procedures.